STAA icon

STAAR Surgical

16.96 USD
+0.43
2.60%
Updated Apr 22, 1:21 PM EDT
1 day
2.60%
5 days
-1.28%
1 month
-4.56%
3 months
-26.52%
6 months
-44.25%
Year to date
-29.63%
1 year
-63.57%
5 years
-54.32%
10 years
88.24%
 

About: Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

Employees: 1,211

0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 75

1.37% less ownership

Funds ownership: 99.54% [Q3] → 98.17% (-1.37%) [Q4]

10% less funds holding

Funds holding: 233 [Q3] → 210 (-23) [Q4]

35% less capital invested

Capital invested by funds: $1.82B [Q3] → $1.18B (-$643M) [Q4]

40% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 48

42% less call options, than puts

Call options by funds: $2.4M | Put options by funds: $4.12M

50% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 3 (-3) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$16
6%
downside
Avg. target
$17.40
3%
upside
High target
$20
18%
upside

5 analyst ratings

positive
20%
neutral
80%
negative
0%
Wells Fargo
0%upside
$17
Equal-Weight
Initiated
21 Apr 2025
Stephens & Co.
Mason Carrico
12% 1-year accuracy
3 / 26 met price target
0%upside
$17
Equal-Weight
Reiterated
18 Mar 2025
Canaccord Genuity
Jon Young
29% 1-year accuracy
2 / 7 met price target
0%upside
$17
Hold
Maintained
13 Feb 2025
Stifel
Thomas Stephan
31% 1-year accuracy
4 / 13 met price target
18%upside
$20
Buy
Maintained
12 Feb 2025
Piper Sandler
Matt O'Brien
32% 1-year accuracy
16 / 50 met price target
6%downside
$16
Neutral
Maintained
12 Feb 2025

Financial journalist opinion

Negative
24/7 Wall Street
1 week ago
Tilman Fertitta, Carl Icahn, and More Insiders Return to the Buy Window
Since the beginning of April, market volatility has spiked, due largely to uncertainty about inflation, interest rates, upcoming quarterly reports, and mostly the impact of tariffs and a global trade war on the U.S.
Tilman Fertitta, Carl Icahn, and More Insiders Return to the Buy Window
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
Neutral
Business Wire
1 month ago
STAAR Surgical Announces Realignment of Leadership Structure
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the following changes to right size and realign its leadership structure to better address market needs: Warren Foust, Chief Operating Officer, has been promoted to the newly created role of President and Chief Operating Officer. In this expanded role, Mr. Foust will continue to oversee.
STAAR Surgical Announces Realignment of Leadership Structure
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
NEW YORK CITY, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA
Neutral
Accesswire
1 month ago
Did STAAR Surgical Company Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- STAA
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of STAAR Surgical Company ("STAAR Surgical Company") (NASDAQ:STAA) concerning possible violations of federal securities laws. Staar reported disappointing earnings for Q4 2024, blaming the results on weak demand in China and a drop in refractive procedures.
Did STAAR Surgical Company Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- STAA
Charts implemented using Lightweight Charts™